No price history available.
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TWDm | 180,648 | 166,190 | 147,538 | 160,000 | 163,589 | 156,397 | N/A | N/A |
| Operating profit | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TWDm | 1,398 | 1,890 | -5,090 | -2,874 | 1,518 | 755 | N/A | N/A |
| EPS reported | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Mercuries & Associates Holding, Ltd. operates as an investment holding company with diverse business interests spanning life insurance, retail of everyday commodities and food, pharmaceuticals, and information technology services. Its insurance division provides a comprehensive suite of products, encompassing various life coverage options (lifetime, whole life, variable), health policies (hospitalization, medical, cancer, long-term care, disability), and accident protection (personal, travel, group). Additionally, it offers annuity plans (immediate, deferred, variable) and foreign currency pension products. The retail segment is involved in the procurement and sale of a broad spectrum of goods, ranging from everyday necessities, groceries, alcoholic beverages, and tobacco to fresh produce, medical supplies, infant products, cosmetics, and beauty items. This division also markets branded footwear, apparel, and accessories, alongside operating fast-food establishments serving items like noodles, rice dishes, fried pork chops, Japanese bento sets, and pizzas. Furthermore, it handles the sale and interior decoration of home furnishings, including furniture, cabinets, kitchen equipment, and mattresses. Within its pharmaceutical operations, Mercuries & Associates Holding manufactures active pharmaceutical ingredients (APIs) such as valproic acid and allopurinol. It also produces API intermediates, including diethyl dipropyl malonate and PENT-2 ethyl 2-allyl-2-cyano-3-methylhexanoate, along with specialty chemicals like diethyl ketone. Moreover, the company delivers information technology services, specializing in the planning, development, and implementation of software and hardware solutions for financial systems and public utilities, complemented by ongoing maintenance support. Founded in Taipei, Taiwan, in 1965, the company officially changed its name from Mercuries & Associates, Ltd. to Mercuries & Associates Holding, Ltd. in January 2015.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Mercuries & Associates Holding, Ltd. (2905.TW)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Mercuries & Associates Holding, Ltd. operates as an investment holding company with diverse business interests spanning life insurance, retail of everyday commodities and food, pharmaceuticals, and information technology services. Its insurance division provides a comprehensive suite of products, encompassing various life coverage options (lifetime, whole life, variable), health policies (hospitalization, medical, cancer, long-term care, disability), and accident protection (personal, travel, group). Additionally, it offers annuity plans (immediate, deferred, variable) and foreign currency pension products. The retail segment is involved in the procurement and sale of a broad spectrum of goods, ranging from everyday necessities, groceries, alcoholic beverages, and tobacco to fresh produce, medical supplies, infant products, cosmetics, and beauty items. This division also markets branded footwear, apparel, and accessories, alongside operating fast-food establishments serving items like noodles, rice dishes, fried pork chops, Japanese bento sets, and pizzas. Furthermore, it handles the sale and interior decoration of home furnishings, including furniture, cabinets, kitchen equipment, and mattresses. Within its pharmaceutical operations, Mercuries & Associates Holding manufactures active pharmaceutical ingredients (APIs) such as valproic acid and allopurinol. It also produces API intermediates, including diethyl dipropyl malonate and PENT-2 ethyl 2-allyl-2-cyano-3-methylhexanoate, along with specialty chemicals like diethyl ketone. Moreover, the company delivers information technology services, specializing in the planning, development, and implementation of software and hardware solutions for financial systems and public utilities, complemented by ongoing maintenance support. Founded in Taipei, Taiwan, in 1965, the company officially changed its name from Mercuries & Associates, Ltd. to Mercuries & Associates Holding, Ltd. in January 2015.